CompanyTCRTNasdaqFort Lauderdale, FL

Alaunos Therapeutics, Inc.

Alaunos Therapeutics develops ALN1003, an oral small-molecule candidate for obesity and metabolic disorders.

SEC EDGAR ClinicalTrials.gov alaunos.com

8-KSep 22Latest SEC filing, period to Sep 18

Sep 30Latest story

September 2026

Phase 1b indibulin-capecitabine trial ended early after no dose-limiting toxicity seen

Sep 30Trial updateAlaunos Therapeutics, Inc.capecitabine

Alaunos Therapeutics trial of darinaparsin in blood cancers ended early, record updated

Sep 30Trial updateAlaunos Therapeutics, Inc.

Alaunos Therapeutics trial of darinaparsin in liver cancer ends after first stage

Sep 30Trial updateAlaunos Therapeutics, Inc.

Alaunos Therapeutics trial of palifosfamide plus doxorubicin in sarcoma ended early after interim an

Sep 30Trial updateAlaunos Therapeutics, Inc.doxorubicin

Alaunos closes registered direct offering, gross proceeds about $1.12 million

Sep 22FinancingAlaunos Therapeutics, Inc.